aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Terns Pharmaceuticals, founded with a mission to develop innovative treatments for serious diseases, focuses on liver disease, cancer, and obesity. The company specializes in discovering and developing molecularly-targeted, small-molecule drugs designed to be orally administered. As a clinical-stage biopharmaceutical firm, Terns Pharmaceuticals aims to address unmet medical needs globally through its robust pipeline of product candidates.
Notable figures associated with Terns Pharmaceuticals include experienced industry leaders and scientists who drive its research and development efforts. The company has garnered significant investment from prominent venture capital firms and strategic partners. Key achievements include advancing multiple candidates into clinical trials, demonstrating promising efficacy and safety profiles. Terns Pharmaceuticals' impact lies in its potential to transform treatment paradigms for serious diseases, offering hope to patients worldwide.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Drug Development
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Pharmaceutical, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Terns Pharmaceuticals founded?
Terns Pharmaceuticals was founded in 2016.
Where is Terns Pharmaceuticals's headquarters located?
Terns Pharmaceuticals's headquarters is located in Foster City, CA, US.
When was Terns Pharmaceuticals's last funding round?
Terns Pharmaceuticals's most recent funding round was for $86.3M (USD) in December 2022.
How many employees does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 30 employees as of Feb 6, 2024.
How much has Terns Pharmaceuticals raised to-date?
As of July 05, 2023, Terns Pharmaceuticals has raised a total of $348.3M (USD) since Dec 20, 2022.
Add Comparison
Total Raised to Date
$348.3M
USD
Last Update Dec 20, 2022
Last Deal Details
$86.3M
USD
Dec 20, 2022
Post Ipo Equity
Total Employees Over Time
30
As of Feb 2024
Terns Pharmaceuticals Address
1065 East Hillsdale
Suite 100
Foster City,
California
94404
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts